PT-141

Overview

PT-141 (generic name: bremelanotide, brand name: Vyleesi) is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (α-MSH) that functions as a selective melanocortin receptor agonist. It was developed by Palatin Technologies as a refined metabolite-derived analog of Melanotan II — the tanning peptide that famously caused spontaneous erections in nine out of ten male volunteers during early human testing, prompting an entirely new research direction. Unlike Viagra, Cialis, and other PDE5 inhibitors that work by increasing blood flow to genital tissue in response to existing arousal, PT-141 works upstream in the sexual response cascade — directly activating the neural circuits in the brain responsible for generating sexual desire and arousal. This central nervous system mechanism makes it the first and only FDA-approved on-demand treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, approved in June 2019 as Vyleesi. It is not FDA approved for men, though off-label use for male sexual dysfunction is growing with a Phase 2 clinical trial of bremelanotide for erectile dysfunction launched in 2024. PT-141's central mechanism is particularly clinically meaningful for patients whose sexual dysfunction stems from reduced central drive — including those with psychogenic dysfunction, stress-related libido loss, or failure to respond to PDE5 inhibitors.

Mechanism of Action

1. MC3R and MC4R Agonism — Central Nervous System [1] — PT-141 selectively activates melanocortin-3 receptors (MC3R) and melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system — brain regions governing sexual motivation, reward, and arousal. This selectivity contrasts with Melanotan II which non-selectively activates all five melanocortin receptor subtypes including MC1R (pigmentation) and produces a broader range of side effects.
2. Dopamine Release in Reward Circuits [2] — MC4R activation by PT-141 in the medial preoptic area of the hypothalamus triggers dopamine release into reward and motivation centers including the nucleus accumbens. This dopaminergic activation generates sexual desire itself rather than simply facilitating physical response to pre-existing desire — a fundamentally different mechanism from vascular-targeted therapies.
3. Central vs. Peripheral Mechanism [3] — PDE5 inhibitors (sildenafil, tadalafil) work peripherally — they enhance blood flow in genital tissue in response to stimulation that already exists. PT-141 works centrally — it acts on the brain's arousal pathways to generate sexual desire and arousal from the neurological level up. This is why PT-141 can be effective in patients who fail PDE5 inhibitor therapy and why it addresses psychogenic and desire-based sexual dysfunction rather than purely vascular dysfunction.
4. Neurotransmitter Pathway Modulation [4] — Based on preclinical studies, bremelanotide acts on physiologic and neurobiologic components of sexual function by modulating neurotransmitter pathways involved in sexual desire and arousal — including dopaminergic, serotonergic, and melanocortinergic signaling.

Key Research Areas

1. Female HSDD — RECONNECT Phase 3 Trials [4] — The FDA approval was based on two parallel Phase 3 clinical trials (RECONNECT studies 301 and 302) enrolling over 1,200 premenopausal women with HSDD. The trials demonstrated statistically significant and clinically meaningful improvements in sexual desire and reductions in distress with 1.75 mg bremelanotide administered as needed. A 52-week open-label extension confirmed sustained efficacy and a favorable long-term safety profile.
2. Male Erectile Dysfunction — Off-Label Research [2] — Early clinical trials established bremelanotide's ability to produce erectile responses in men including those who failed PDE5 inhibitor therapy. A Phase 2 study launched in 2024 by Palatin Technologies evaluating bremelanotide combined with a PDE5 inhibitor in 50 PDE5-nonresponsive men aims to establish formal male ED efficacy data toward potential FDA approval. Earlier studies showed 67% of PT-141 recipients reported improved erections vs 33% placebo, and a study in 180 sildenafil-resistant men showed 62% improvement with PT-141.
3. PDE5 Inhibitor Non-Responders [2] — A key clinical distinction for PT-141 is its different mechanism from PDE5 inhibitors. A study examining the combination of bremelanotide and sildenafil in inadequate PDE5i responders found the combination induced a clinically significant enhanced erectile response — suggesting complementary rather than redundant mechanisms.
4. Historical Discovery — The Melanotan II Connection [2] — The development history of PT-141 is notable: a University of Arizona researcher self-administered Melanotan II and unexpectedly experienced a prolonged erection — the accidental discovery that melanocortin receptor activation profoundly affects sexual function. This led to the deliberate development of bremelanotide as a more selective, refined analog specifically targeting sexual dysfunction without the non-selective receptor activation of Melanotan II.

Observed Benefits in Research

1. FDA-approved for HSDD in premenopausal women with demonstrated Phase 3 efficacy
2. Statistically significant improvements in sexual desire scores vs placebo
3. Significant reductions in sexual distress (FSDS-DAO scores)
4. Increased number of satisfying sexual events
5. 67% improvement in erectile function vs 33% placebo in men
6. 62% improvement in sildenafil-resistant erectile dysfunction study
7. Clinically significant enhanced erectile response when combined with PDE5 inhibitors
8. Non-hormonal mechanism — suitable for women who cannot use estrogen or testosterone therapies
9. On-demand dosing with onset within 45 minutes

Pharmacokinetics

1. Structure: Cyclic heptapeptide derived from α-MSH — 7 amino acids
2. Dose: 1.75 mg subcutaneous injection (FDA-approved female dose); 1.25–2 mg studied in males
3. Administration: Subcutaneous injection at least 45 minutes before sexual activity
4. Maximum frequency: One dose per 24 hours; no more than 8 doses per month
5. Mean maximum plasma concentration: 72.8 ng/mL after subcutaneous administration
6. Onset: Within 45 minutes to 1 hour

FDA Approval Status

PT-141 (bremelanotide) is FDA approved as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not FDA approved for use in men — off-label prescribing by physicians is legally permissible. A Phase 2 trial for male erectile dysfunction was launched in 2024. Note: PT-141 is distinct from Melanotan II — Melanotan II is not FDA approved for any indication. PT-141/bremelanotide is a selective refined analog that achieved full FDA approval.

Side Effects and Limitations

Most common side effects from Phase 3 trials and 52-week extension: nausea (40.4%), flushing (20.6%), headache (12.0%). These are generally transient and mild. Rare: temporary blood pressure increases (mean 1.9 mmHg systolic), hyperpigmentation at injection site. Contraindications: cardiovascular disease or high cardiovascular risk — blood pressure effects require caution. Not recommended with alcohol due to combined cardiovascular effects. Maximum 8 doses per month to avoid cumulative side effects. Intranasal formulation was discontinued in early development due to greater blood pressure effects — subcutaneous injection is the standard route.

Related Peptides

References

1. PMC. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/
2. Men's Reproductive Health. PT-141 for Men: A New Drug to Treat Erectile Dysfunction and Low Libido. 2025. https://mensreproductivehealth.com/pt-141-for-men-a-new-drug-to-treat-erectile-dysfunction-and-low-libido/
3. Form Blends. PT-141 / Bremelanotide (Vyleesi): FDA-Approved Peptide for Hypoactive Sexual Desire — Complete Guide. 2025. https://formblends.com/research/specialty/pt141-bremelanotide-sexual-dysfunction
4. PMC. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/